Recent Advances in Parkinson�s Disease Research, Volume 252, represents a follow-up on two previous volumes presented in the Progress in Brain Research series, Volumes 193 and 193, both published in 2010. It contains a collection of overview articles written by leading researchers in Parkinson's, discussing the most important advances made in basic, translational and clinical research. Topics of note in this new release include What can we learn from iPS cell models of PD, What can we learn from animal models of PD?, Molecular basis of selective neuronal vulnerability in PD, Role of innate and adaptive immunity in Parkinson�s disease, and much more.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
What we can learn from iPSC-derived cellular models of Parkinson's disease?Maria Claudia Caiazza, Charmaine Lang and Richard Wade-Martins
2. Animal models for preclinical Parkinson's research: An update and critical appraisal
M. Angela Cenci and Anders Bj?rklund
3. Selective neuronal vulnerability in Parkinson's disease
Patricia Gonzalez-Rodriguez, Enrico Zampese and D. James Surmeier
4. Mechanisms of alpha-synuclein toxicity: An update and outlook
In?s Caldeira Br?s, Mary Xylaki and Tiago Fleming Outeiro
5. The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications
Katarzyna Z. Kuter, M. Angela Cenci and Anna R. Carta
6. Innate and adaptive immune responses in Parkinson's disease
Aubrey M. Schonhoff, Gregory P. Williams, Zachary D. Wallen, David G. Standaert and Ashley S. Harms
7. Pathways of protein synthesis and degradation in PD pathogenesis
Rebekah G. Langston and Mark R. Cookson
8. Endosomal sorting pathways in the pathogenesis of Parkinson's disease
Lindsey A. Cunningham and Darren J. Moore
9. New players in basal ganglia dysfunction in Parkinson's disease
Sara Meoni, Rubens Gisbert Cury and Elena Moro
10. Prodromal PD: A new nosological entity
Eva Schaeffer, Ronald B. Postuma and Daniela Berg
11. The gut microbiome in Parkinson's disease: A culprit or a bystander?
Ali Keshavarzian, Phillip Engen, Salvatore Bonvegna and Roberto Cilia
12. Novel approaches to counter protein aggregation pathology in Parkinson's disease
Simon R.W. Stott, Richard K. Wyse and Patrik Brundin
13. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
Tom Foltynie and Dilan Athauda
14. Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson's disease
Per Petersson, Andre
